Inhibition of lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression by 4-[(2'-O-acetyl-α-L-rhamnosyloxy) benzyl]isothiocyanate from moringa oleifera

Nutrition and Cancer

Volumn 63, Issue 6, 2011, Pages 971-982

  Park, Eun Jung ^a   Cheenpracha, Sarot ^a   Chang, Leng Chee ^a   Kondratyuk, Tamara P ^a   Pezzuto, John M ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2' O ACETYL ALPHA LEVO RHAMNOSYLOXY)BENZYL] SOTHIOCYANATE; BENZYL ISOTHIOCYANATE; CYCLOOXYGENASE 2; I KAPPA B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOTHIOCYANIC ACID DERIVATIVE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SULFORAPHANE; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL GROWTH; DNA BINDING; DRUG EFFECT; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE REPRESSION; IC 50; MACROPHAGE; MORINGA OLEIFERA; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; CELL LINE; CYCLOOXYGENASE 2; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOTHIOCYANATES; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MORINGA OLEIFERA; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; PLANT EXTRACTS; RHAMNOSE; SIGNAL TRANSDUCTION;

MORINGA OLEIFERA;

EID: 80051770614     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.589960     Document Type: Article

References (66)

1. Anwar F, Latif S, Ashraf M, and Gilani AH: Moringa oleifera: A food plant with multiple medicinal uses. Phytother Res 21, 17-25, 2007.
2. Debnath S, Biswas D, Ray K, and Guha D: Moringa oleifera induced potentiation of serotonin release by 5-HT(3) receptors in experimental ulcer model. Phytomedicine 18, 91-95, 2011.
3. ThurberMDand Fahey JW: Adoption of Moringa oleifera to combat undernutrition viewed through the lens of the "diffusion of innovations" theory. Ecol Food Nutr 48, 212-225, 2009.
4. Ndabigengeserea A and Narasiah KS: Quality of water treated by coagulation using Moringa oleifera seeds. Helv Chim Acta 32, 781-791, 1998.
5. Rashid U, Anwar F, Moser BR, and Knothe G: Moringa oleifera oil: A possible source of biodiesel. Bioresour Technol 99, 8175-8179, 2008.
6. Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, et al.: An antitumor promoter from Moringa oleifera Lam. Mutat Res 440, 181-188, 1999.
7. Francis JA, Jayaprakasam B, Olson LK, and Nair MG: Insulin secretagogues from Moringa oleifera with cyclooxygenase enzyme and lipid peroxidation inhibitory activities. Helv Chem Acta 87, 317-326, 2004.
8. Cheenpracha S, Park EJ, Yoshida WY, Barit C, Wall M, et al.: Potential antiinflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits. Bioorg Med Chem 18, 6598-6602, 2010.
9. Cheenpracha S, Park EJ, Rostama B, Pezzuto JM, and Chang LC: Inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells by the norsesterterpene peroxide, epimuqubilin A. Mar Drugs 8, 429-437, 2010.
10. Anderson N and Borlak J: Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60, 311-357, 2008.
11. Kanwar JR, Kanwar RK, Burrow H, and Baratchi S: Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem 16, 2373-2394, 2009.
12. Coussens LM andWerb Z: Inflammation and cancer. Nature 420, 860-867, 2002.
13. Chung CP, Avalos I, Raggi P, and Stein CM: Atherosclerosis and inflammation: Insights from rheumatoid arthritis. Clin Rheumatol 26, 1228-1233, 2007.
14. Wyss-Coray T: Inflammation inAlzheimer disease: Driving force, bystander or beneficial response? Nature Med 12, 1005-1015, 2006.
15. Schottenfeld D and Beebe-Dimmer J: Chronic inflammation: A common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56, 69-83, 2006.
16. Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, et al.: Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 163, 1537-1544, 1999.
17. Bingle L, Brown NJ, and Lewis CE: The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196, 254-265, 2002.
18. Harris RE: Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17, 55-67, 2009.
19. Xu W, Liu LZ, Loizidou M, Ahmed M, and Charles IG: The role of nitric oxide in cancer. Cell Res 12, 311-320, 2002.
20. Pålsson-McDermott EM and O'Neill LA: Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113, 153-162, 2004.
21. Murakami A and Ohigashi H: Targeting NOX, INOS and COX-2 in inflammatory cells: Chemoprevention using food phytochemicals. Int J Cancer 121, 2357-2363, 2007.
22. Heiss E, Herhaus C, Klimo K, Bartsch H, and Gerhäuser C: Nuclear factor γB is a molecular target for sulforaphane-mediated antiinflammatory mechanisms. J Biol Chem 276, 32008-32015, 2001.
23. Chen YH, Dai HJ, and Chang HP: Suppression of inducible nitric oxide production by indole and isothiocyanate derivatives from Brassica plants in stimulated macrophages. Planta Med 69, 696-700, 2003.
24. Rose P, Won YK, Ong CN, and Whiteman M: ß-Phenylethyl and 8- methylsulphinyloctyl isothiocyanates, constituents of watercress, suppress LPS induced production of nitric oxide and prostaglandin E2 in RAW264.7 macrophages. Nitric Oxide 12, 237-243, 2005.
25. Prawan A, Saw CL, Khor TO, Keum YS, Yu S, et al.: Anti-NF-γB and antiinflammatory activities of synthetic isothiocyanates: Effect of chemical structures and cellular signaling. Chem Biol Interact 179, 202-211, 2009.
26. Lee YM, Seon MR, Cho HJ, Kim JS, and Park JH: Benzyl isothiocyanate exhibits anti-inflammatory effects in murine macrophages and in mouse skin. J MolMed 87, 1251-1261, 2009.
27. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, and Byrns RE: Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci USA 90, 8103-8107, 1993.
28. Xagorari A, Roussos C, and Papapetropoulos A: Inhibition of LPSstimulated pathways in macrophages by the flavonoid luteolin. Br J Pharmacol 136, 1058-1064, 2002.
29. Jang SI, Kim HJ, Kim YJ, Jeong SI, and You YO: Tanshinone IIA inhibits LPS-induced NF-γB activation in RAW 264.7 cells: Possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 542, 1-7, 2006.
30. You M, Wickramaratne DB, Silva GL, Chai H, Chagwedera TE, et al.: (-)- Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J Nat Prod 58, 598-604, 1995.
31. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254, 1976.
32. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159, 1987.
33. Zhao L, Tao JY, Zhang SL, Jin F, Pang R, et al.: N-Butanol extract from Melilotus suaveolens Ledeb affects pro- and antiinflammatory cytokines and mediators. Evid Based Complement Alternat Med 7, 97-106, 2010.
34. Park HJ, Chung HJ, Min HY, Park EJ, Hong JY, et al.: Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochem Pharmacol 71, 21-31, 2005.
35. Luqman S and Pezzuto JM: NFγB: A promising target for natural products in cancer chemoprevention. Phytother Res 24, 949-963, 2010.
36. Chun KS, Keum YS, Han SS, Song YS, Kim SH, et al.: Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-γB activation. Carcinogenesis 24, 1515-1524, 2003.
37. Chakravortty D, Kato Y, Sugiyama T, Koide N, Mu MM, et al.: The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: A role of Raf-1 in lipopolysaccharide signaling. J Immunol 166, 2011-2017, 2001.
38. Chen BC and Lin WW: PKC- and ERK-dependent activation of IγB kinase by lipopolysaccharide inmacrophages: Enhancement by P2Y receptormediated CaMK activation. Br J Pharmacol 134, 1055-1065, 2001.
39. AgaM,Watters JJ, Pfeiffer ZA,Wiepz GJ, Sommer JA, et al.: Evidence for nucleotide receptor modulation of cross talk between MAP kinase and NF- γB signaling pathways in murine RAW 264.7 macrophages. Am J Physiol Cell Physiol 286, C923-C930, 2004.
40. Jiang B, Xu S, Hou X, Pimentel DR, Brecher P, et al.: Temporal control of NF-γB activation by ERK differentially regulates interleukin-1ß- induced gene expression. J Biol Chem 279, 1323-1329, 2004.
41. Suh SJ, Chung TW, Son MJ, Kim SH, Moon TC, et al.: The naturally occurring biflavonoid, ochnaflavone, inhibits LPS-induced iNOS expression, which is mediated by ERK1/2 via NF-γB regulation, in RAW264.7 cells. Arch Biochem Biophys 447, 136-146, 2006.
42. Rubio AR and Morales-Segura MA: Nitric oxide, an iceberg in cardiovascular physiology: Far beyond vessel tone control. Arch Med Res 35, 1-11, 2004.
43. Wallace JL and Miller MJ: Nitric oxide in mucosal defense: A little goes a long way. Gastroenterology 119, 512-520, 2000.
44. ContestabileAand Ciani E:Role of nitric oxide in the regulation of neuronal proliferation, survival, and differentiation. Neurochem Int 45, 903-914, 2004.
45. Patel RP,McAndrew J, Sellak H, White CR, Jo H, et al.: Biological aspects of reactive nitrogen species. Biochim Biophys Acta 1411, 385-400, 1999.
46. Hersh EV, Lally ET, and Moore PA: Update on cyclooxygenase inhibitors: Has a third COX isoform entered the fray? Curr Med Res Opin 21, 1217-1226, 2005.
47. Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, et al.: Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59, 51-64, 2006.
48. Kundu JK and Surh YJ: Inflammation: Gearing the journey to cancer. Mutat Res 659, 15-30, 2008.
49. Cheung KL and Kong AN: Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 12, 87-97, 2010.
50. Chung FL, Conaway CC, Rao CV, and Reddy BS: Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21, 2287-2291, 2000.
51. Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, et al.: Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27, 2038-3046, 2006.
52. Park EJ and Pezzuto JM: Botanicals in cancer chemoprevention. Cancer Metastasis Rev 21, 231-255, 2002.
53. WarinR,ChambersWH, PotterDM,and Singh SV: Prevention ofmammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res 69, 9473-9480, 2009.
54. Hecht SS, Kenney PM,Wang M, and Upadhyaya P: Benzyl isothiocyanate: An effective inhibitor of polycyclic aromatic hydrocarbon tumorigenesis in A/J mouse lung. Cancer Lett 187, 87-94, 2002.
55. von Weymarn LB, Chun JA, and Hollenberg PF: Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: Potential for chemoprevention in smokers. Carcinogenesis 27, 782-790, 2006.
56. Miyoshi N, Takabayashi S, Osawa T, and Nakamura Y. Benzyl isothiocyanate inhibits excessive superoxide generation in inflammatory leukocytes: Implication for prevention against inflammation-related carcinogenesis. Carcinogenesis 25, 567-575, 2004.
57. Feghali CA and Wright TM: Cytokines in acute and chronic inflammation. Front Biosci 2, d12-d26, 1997.
58. Greten FR and Karin M: The IKK/NF-γB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 206, 193-199, 2004.
59. Kim SH, Kim J, and Sharma RP: Inhibition of p38 and ERK MAP kinases blocks endotoxin-induced nitric oxide production and differentially modulates cytokine expression. Pharmacol Res 49, 433-439, 2004.
60. Choi MS, Lee SH, Cho HS, Kim Y, Yun YP, et al.: Inhibitory effect of obovatol on nitric oxide production and activation of NF-γB/MAP kinases in lipopolysaccharide-treated RAW 264.7 cells. Eur J Pharmacol 556, 181-189, 2007.
61. Lai CS, Lee JH, Ho CT, Liu CB, Wang JM, et al.: Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF-γB, STAT3 and C/EBP signaling pathways. J Agric Food Chem 57, 10990-10998, 2009.
62. Senthil Kumar KJ and Wang SY: Lucidone inhibits iNOS and COX-2 expression in LPS-induced RAW 264.7 murine macrophage cells via NF- γB and MAPKs signaling pathways. Planta Med 75, 494-500, 2009.
63. Chiu FL and Lin JK: Tomatidine inhibits iNOS andCOX-2 through suppression of NF-γB and JNK pathways in LPS-stimulated mouse macrophages. FEBS Lett 582, 2407-2412, 2008.
64. Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, et al.: Antiinflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-γB, JNK, and p38 MAPK inactivation. Eur J Pharmacol 586, 340-349, 2008.
65. Chun KS and Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: Potential molecular targets for chemoprevention. Biochem Pharmacol 68, 1089-1100, 2004.
66. PautzA,Art J, Hahn S, Nowag S,Voss C, et al.: Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 23, 75-93, 2010.